GlassScriptPhysician profile
Dulabh Kaur Monga
NPI 1578564019
$44,491.27
in general payments reported to CMS, 2019-2025
21 companies · $8,337 in 2025
The $8,337 reported for 2025 was more than what 79% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $566 · 2020: $255 · 2021: $166 · 2022: $9,401 · 2023: $6,112 · 2024: $20K · 2025: $8,337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Consulting Fee: $2,875 · Food and Beverage: $1,448 · Travel and Lodging: $804 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,858.00 |
| Consulting Fee | $2,875.00 |
| Food and Beverage | $1,447.57 |
| Travel and Lodging | $803.61 |
| Education | $119.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24,150.89 | 2019-2025 | Imfinzi |
| E.R. Squibb & Sons, L.L.C. | $15,028.03 | 2019-2024 | Opdivo |
| Amgen INC. | $3,860.73 | 2019-2025 | Vectibix |
| Astellas Pharma US INC | $388.99 | 2019-2023 | |
| Intera Oncology, INC | $315.76 | 2021-2023 | Intera 3000 Implantable Pump |
| Abbvie INC. | $284.17 | 2022-2025 | |
| Lilly USA, LLC | $95.89 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $94.68 | 2025 | Onivyde |
| Merck Sharp & Dohme LLC | $46.50 | 2019-2023 | Keytruda |
| Eisai INC. | $41.70 | 2024-2025 | |
| Coherus Oncology, INC. | $41.29 | 2025 | Loqtorzi |
| Axsome Therapeutics, INC. | $35.00 | 2025 | Auvelity |
| Gilead Sciences, INC. | $30.65 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.75 | 2019 | |
| Celgene Corporation | $13.91 | 2023 | Reblozyl |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $12.04 | 2019 | |
| Seagen INC. | $12.04 | 2019 | |
| Clovis Oncology, INC. | $12.04 | 2019 | |
| Genentech USA, INC. | $11.21 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dulabh Monga listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.